Prying STING Open: How an Approved Drug Marks an Inflammatory Protein for Destruction

Aging is accompanied by a smoldering, chronic inflammation, and one of its suspected drivers is STING, a protein that helps cells respond to DNA where it should not be. In this pathway, the sensor cGAS detects stray DNA and produces a messenger molecule that switches STING on. When STING remains abnormally active, it keeps the inflammatory alarm ringing, yet no drug directed against it has been approved for clinical use. A study published on September 17, 2026 in Nature Communications by a team at the Chinese Academy of Sciences approaches the problem from an unexpected angle: a high-throughput screen turned up omaveloxolone, a drug already approved for Friedreich’s ataxia, as a potent STING degrader.

The compound binds tightly, without forming a covalent bond, to the base of the domain that STING uses to sense its activating signal. There it acts like a crowbar, hindering the domain’s closure, exposing hydrophobic surfaces, and lowering the protein’s thermal stability. The authors propose that this destabilized shape is recognized by HUWE1, an enzyme that attaches ubiquitin chains (a molecular discard tag), to three lysines of STING, after which the proteasome destroys the tagged protein. The effect is striking: half-maximal degradation occurred at about 118 nanomolar, and up to 98.6% of STING disappeared.

In aged male mice, the drug depleted STING, dampened downstream inflammatory signaling, and ameliorated inflammatory features of aging. Caution is nevertheless warranted. The animal work was limited to male mice, and omaveloxolone is also an established activator of NRF2, an antioxidant pathway, so the benefit probably reflects two effects at once rather than STING removal alone. The role of HUWE1, moreover, is presented as a proposal rather than an established fact.

Even so, degrading rather than blocking a target offers a mechanistic framework worth watching: destabilizing a protein until the cell’s own quality control removes it may complement conventional inhibition, and repurposing an approved compound could shorten the path to the clinic, although a new indication would still require its own trials. Among the many open questions are whether the concentrations reachable in patients would suffice and how much STING can be removed without compromising its antiviral defense function, all of which invite further research.